Addition of Darbepoetin Alfa to Dose-Dense Chemotherapy: Results From a Randomized Phase II Trial in Small-Cell Lung Cancer Patients Receiving Carboplatin Plus Etoposide
- 1 January 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 62-69
- https://doi.org/10.3816/clc.2011.n.009
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomesBritish Journal of Cancer, 2010
- Erythropoietins should be used according to guidelinesThe Lancet Oncology, 2008
- September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating AgentsThe Oncologist, 2008
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Erythropoietin, the FDA, and OncologyThe New England Journal of Medicine, 2007
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEuropean Journal of Cancer, 2007
- Erythropoietin to treat anaemia in patients with head and neck cancerThe Lancet, 2004
- Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancerBritish Journal of Cancer, 1999
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Decreased Erythropoietin Response in Patients with the Anemia of CancerThe New England Journal of Medicine, 1990